Patents by Inventor Ulrik Mouritzen

Ulrik Mouritzen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Danegaptide for Use in the Treatment or Prevention of a Kidney Disease
    Publication number: 20240108598
    Abstract: The present invention relates to danegaptide, or a pharmaceutically acceptable salt thereof for use in the treatment of a kidney disease, such as a chronic kidney disease, for example Diabetic Nephropathy and/or Chronic Kidney Disease.
    Type: Application
    Filed: February 3, 2022
    Publication date: April 4, 2024
    Applicant: Breye Therapeutics ApS
    Inventors: Paul Squires, Claire Hills, Ulrik Mouritzen
  • Gap junction intercellular communication modulators and their use for the treatment of diabetic eye disease
    Patent number: 11324799
    Abstract: The use of gap junction intercellular communication (GJIC) modulators in the treatment or prevention of diabetic eye disease is disclosed, and more particularly to their use for the treatment or prevention of early stage diabetic retinopathy and diabetic macular edema by inhibiting apoptosis of retinal endothelial cells and inhibiting pericyte loss.
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: May 10, 2022
    Assignees: ZEALAND PHARMA A/S, BOSTON MEDICAL CENTER CORPORATION
    Inventors: Bjarne Due Larsen, Ulrik Mouritzen, Dongjoon Kim, Sayon Roy
  • GAP JUNCTION INTERCELLULAR COMMUNICATION MODULATORS AND THEIR USE FOR THE TREATMENT OF DIABETIC EYE DISEASE
    Publication number: 20200054602
    Abstract: The use of gap junction intercellular communication (GJIC) modulators in the treatment or prevention of diabetic eye disease is disclosed, and more particularly to their use for the treatment or prevention of early stage diabetic retinopathy and diabetic macular edema by inhibiting apoptosis of retinal endothelial cells and inhibiting pericyte loss.
    Type: Application
    Filed: May 4, 2018
    Publication date: February 20, 2020
    Applicants: ZEALAND PHARMA A/S, BOSTON MEDICAL CENTER CORPORATION
    Inventors: Bjarne Due LARSEN, Ulrik MOURITZEN, Dongjoon KIM, Sayon ROY
  • DOSAGE REGIMES FOR THE ADMINISTRATION OF GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) ANALOGUES
    Publication number: 20200000883
    Abstract: Dosage regimes for the administration of glucagon-like-peptide-2 (GLP-2) analogues and their medical use are disclosed, for example in the treatment and/or prevention of stomach and bowel-related disorders and for ameliorating side effects of chemotherapy and radiation therapy. Dosage regimes for the administration of glucagon-like-peptide-2 (GLP-2) analogues for inducing longitudinal growth of the intestines are described, for example for the treatment of patients with short bowel syndrome (SBS). Medical uses for adjusting the volume of parenteral support (PS) provided to subjects receiving treatment with GLP-2 analogues in response to the treatment and to algorithms for determining PS volume changes are also described.
    Type: Application
    Filed: July 15, 2019
    Publication date: January 2, 2020
    Inventors: Kim SONNE, Ulrik MOURITZEN, Peter GLERUP, Palle Bekker JEPPESEN
  • Neoadjuvant treatment of cancer with proleukin
    Patent number: 8961950
    Abstract: Low doses of IL-2 are administered locally and neo-adjuvantly to patients with early stages of the disease. This will result in local high concentrations of IL-2 within the relevant tumor draining lymph nodes. Patients with only early stages of disease will be more responsive to immunotherapy with the expectation of improved survival of patients compared to current therapy standards.
    Type: Grant
    Filed: August 10, 2011
    Date of Patent: February 24, 2015
    Inventors: Ulrik Mouritzen, Christiane Voit
  • NEOADJUVANT TREATMENT OF CANCER WITH PROLEUKIN
    Publication number: 20130156730
    Abstract: Low doses of IL-2 are administered locally and neo-adjuvantly to patients with early stages of the disease. This will result in local high concentrations of IL-2 within the relevant tumour draining lymph nodes.
    Type: Application
    Filed: August 10, 2011
    Publication date: June 20, 2013
    Inventors: Ulrik Mouritzen, Christiane Voit